Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

被引：0
|
作者：
Hart, A. [1 ,2 ]
Martin-Arranz, M. D. [3 ]
Laharie, D. [4 ]
Matsuoka, K. [5 ]
Dhesi, E. [6 ]
Redondo, I. [6 ]
Baygani, S. [6 ]
Zaremba-Pechmann, L. [7 ]
Samaan, K. [6 ]
Navabi, S. [8 ]
机构：
[1] St Marks Hosp, London, England
[2] Imperial Coll, Dept Metab Digest & Reprod, London, England
[3] Hosp La Paz Inst Hlth Res, Dept Gastroenterol, Madrid, Spain
[4] Univ Bordeaux, Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France
[5] Toho Univ, Div Gastroenterol & Hepatol, Sakura Med Ctr, Dept Internal Med, Sakura, Japan
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] HaaPACS GmBH, Stat, Schriesheim, Germany
[8] United Med Doctors, Gastroenterol Hepatol & Obes Med, Long Beach, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP14
引用
收藏
页码：I27 / I28
页数：2
相关论文
共 50 条
  • [1] EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Navabi, Seyedehsan
    D'Haens, Geert
    Samaan, Karen H.
    Li, Xingyuan
    Arora, Vipin
    Redondo, Isabel
    Danese, Silvio
    GASTROENTEROLOGY, 2023, 164 (06) : S1089 - S1089
  • [2] Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis
    Navabi, S.
    D'Haens, G.
    Samaan, K. H.
    Li, X.
    Arora, V.
    Redondo, I.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 598 - 598
  • [3] Endoscopic and Histologic Remission After 2 Years Treatment With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Margo, Fernando
    Peyrin-Biroulet, Laurent
    Kobayashi, Taku
    Jairath, Vipul
    Walsh, Alissa
    Christensen, Britt
    Wu, Jianmin
    Park, Gina
    Redondo, Isabel
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S812
  • [4] Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use
    Fung, Simon
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2024, : 433 - 443
  • [5] CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
    Laharie, D.
    Siegel, C. A.
    Samaan, K.
    Fisher, D. A.
    Morris, N.
    Redondo, I.
    Dulai, P. S.
    Jairath, V.
    Gisbert, J. P.
    Matsuoka, K.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S163 - S164
  • [6] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S10 - S11
  • [7] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    GASTROENTEROLOGY, 2020, 158 (03) : S17 - S18
  • [8] Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy
    Laharie, David
    Siegel, Corey A.
    Samaan, Karen
    Fischer, Deborah
    Morris, Nathan
    Redondo, Isabel
    Dulai, Parambir S.
    Jairath, Vipul
    Gisbert, Javier P.
    Matsuoka, Katsuyoshi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S635 - S635
  • [9] MUCOSAL HEALING WITH A SECOND ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS AFTER THE FAILURE OF THE PREVIOUS ANTI-TNF TREATMENT
    Papa, A.
    Pugliese, D.
    De Vitis, I.
    D'Aversa, F.
    Landi, R.
    Felice, C.
    Guidi, L.
    Armuzzi, A.
    Rapaccini, G. L.
    DIGESTIVE AND LIVER DISEASE, 2017, 49 : E203 - E203
  • [10] EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
    D'Haens, Geert
    Higgins, Peter D.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard
    Redondo, Isabel
    Escobar, Rodrigo
    Morris, Nathan
    Kobayashi, Taku
    GASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1086
12345